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Background: There are few studies on the epidemiology of epilepsy in large populations in Low and Middle
Income Countries (LMIC). Most studies in these regions use two-stage population-based screening surveys, which
are time-consuming and costly to implement in large populations required to generate accurate estimates. We
examined the sensitivity and specificity of a three-stage cross-sectional screening methodology in detecting active
convulsive epilepsy (ACE), which can be embedded within on-going census of demographic surveillance systems.
We validated a three-stage cross-sectional screening methodology on a randomly selected sample of participants of
a three-stage prevalence survey of epilepsy. Diagnosis of ACE by an experienced clinician was used as ‘gold
standard’. We further compared the expenditure of this method with the standard two-stage methodology.
Results: We screened 4442 subjects in the validation and identified 35 cases of ACE. Of these, 18 were identified as
false negatives, most of whom (15/18) were missed in the first stage and a few (3/18) in the second stage of the
three-stage screening. Overall, this methodology had a sensitivity of 48.6% and a specificity of 100%. It was 37%
cheaper than a two-stage survey.
Conclusion: This was the first study to evaluate the performance of a multi-stage screening methodology used to
detect epilepsy in demographic surveillance sites. This method had poor sensitivity attributed mainly to
stigma-related non-response in the first stage. This method needs to take into consideration the poor sensitivity
and the savings in expenditure and time as well as validation in target populations. Our findings suggest the need
for continued efforts to develop and improve case-ascertainment methods in population-based epidemiological
studies of epilepsy in LMIC.
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Epilepsy is a common non-communicable neurological
condition and a significant cause of disability and mor-
tality [1]. It is estimated to affect nearly 70 million
people worldwide, 90% of who live in low and middle in-
come countries (LMIC) [2]. There is a wide range of
prevalence estimates from studies estimates in LMIC [2].
It is unclear if this heterogeneity is caused by different
methods and/or tools used, many of which have not
been validated in the target populations [3-5].
In high income countries (HIC), researchers utilize
medical and service records to provide epidemiological
data on epilepsy. In LMIC this methodology is unreliable
since there is low usage and/or lack of access to health
care facilities by majority of the population and where
available (e.g. in urban settings) medical records and
diagnostic facilities are often poor [6-10]. Thus single
round surveys (done by non-medical field personnel)
and key informants have been used but these under-
report the prevalence [11]. Two-stage surveys in which
the population is screened with a questionnaire, with the
diagnoses confirmed by clinical evaluation are recom-
mended [12] and have been used in several studies [13-
21]. However, this method is costly to implement in large
populations since the first stage takes considerable time
and the second stage requires qualified medical personnel
who often have to assess a large number of false positives.
With a condition such as epilepsy, there are no simple
diagnostic tests (e.g. blood measurements) and the diag-
nosis depends upon history and assessment by experi-
enced specialists. There are relatively few specialists in
LMIC and they are expensive to employ for epidemio-
logical surveys [22,23]. Epidemiological studies are often
conducted on high-risk populations (e.g. those with a high
prevalence of putative risk factors) [24-26]. These may
generate high estimates of prevalence that are not repre-
sentative of wider populations [27]. In these resource-
limited settings, identification of patients with epilepsy is
further compounded by stigma-related concealment of
patients by their families and/or their symptoms.
These methodological problems may have led to under
ascertainment of epilepsy cases in studies conducted in
LMIC, with the inevitable consequence of incomplete
coverage of target populations for public health inter-
ventions. Thus, there is need to survey larger popula-
tions to provide robust estimates of distribution using
methods that maximise detection of cases with least cost
and effort [11].
To address these issues in epidemiological studies of
epilepsy, we have used a three-stage methodology to
screen large populations within Health and Demo-
graphic Surveillance Systems (HDSS) [28], under the
INDEPTH network (http://www.indepth-network.org/).
Within the HDSS, censuses are conducted 1–3 times ayear, in which non-medical personnel conduct re-
enumeration and vital status registration by interviewing
a senior member of the household. Thus, the screen for
convulsions (first stage of the three-stage methodology)
needs to be embedded within on-going HDSS census to
be administered to the entire population to minimise
cost. In this paper, we determine the sensitivity and spe-
cificity of the three-stage method in detecting active
convulsive epilepsy (ACE) in population-based studies
and compare the expenditure with that of a two-stage
survey.
Methods
The study setting and study population
The study was conducted within the Kilifi HDSS
(KHDSS - http://www.kemri-wellcome.org/khdss/) in
the Coast province of Kenya. The study area covers 891
square kilometers in 15 administrative locations with 40
sub-locations. Demographic surveillance and vital regis-
tration are performed 2–3 times a year.
The residents are mainly Mijikenda, a Bantu grouping
of nine tribes with Giriama (45%), Chonyi (33%) and
Kauma (11%) being most common. About 55% of the
population is considered absolutely poor, per capita in-
come ~ USD 10 per month. The majority (80%) are sub-
sistence farmers and literacy levels are low (about 45%).
Description of the three-stage cross-sectional survey
method (prevalence survey)
Stage 1 (SI): the general population screen
The first stage screens the entire resident population
using a simple two-item tool to detect convulsions
(Additional file 1), which is administered to a senior
member of each household (as a proxy for members of
that household) by a non-medical fieldworker. The ques-
tions were piloted to maximise their sensitivity to detect
individuals with the main symptoms of convulsive epi-
lepsy (i.e. convulsions). This stage uses HDSS census
field staff to screen populations rapidly during their rou-
tine re-enumeration and vital registration.
Stage 2 (SII): the condition-specific screen
People identified with a history of convulsions in SI were
followed-up within a week by different interviewers with
more extensive training in epilepsy who administered a
more detailed and specific questionnaire to the individ-
ual or their care givers (if they were minors or cogni-
tively challenged) to identify possible cases. This tool
was based on that used in other studies [12] (Additional
file 2). This stage aimed to reduce the number of false
positives by using a tool with higher specificity than that
used in the first stage in order to reduce the cost of
diagnosis in the subsequent stage.
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The respondents identified as potential cases of ACE in
SII were invited for clinical assessments to confirm the
diagnosis within 1–2 weeks of SII. The diagnosis of ACE
was based upon a detailed clinical history taken by an
experienced clinician. ACE was defined as at least two
unprovoked convulsions (tonic and/or clonic seizures),
of which one occurred within 12 months of the clinical
assessment [28,29].
The three-stage survey method identified an individual
as a case of ACE if they were positive in all the three
stages. This three-stage survey method was tested in this
validation study.Assessment of the three-stage methodology using a
survey conducted by clinicians
Sampling and follow-up of the validation sample
A random sample for the validation of the three-stage
survey methodology was selected from the 2008 Kilifi
HDSS population database using the ‘RAND()’ command
in MySQL Version 5 open source database (Oracle Cor-
poration, Redwood Shores, CA, USA). A sample size of
5796 was estimated to determine the sensitivity of the
three-stage method (assumed to be 85%) with a preci-
sion of 13% (i.e., half the width of the 95% Confidence
Interval (95%CI)) [30] in a population with a prevalence
~ 5/1000 [28]. This sample was interviewed in the three
stages of the prevalence survey in 2008 as described
above.Clinical survey (Validation Survey)
To validate the three-stage methodology, everyone in
the random sample had the SII questions administered
by non-medical fieldworkers (independent of their sta-
tus in SI of the three-stage methodology), as well as
being interviewed by experienced clinicians with the
proforma administered in the SIII of the prevalence
survey (this was the Clinical Survey or the “gold
standard” for validating the three-stage method (‘test’)
described above). This validation was conducted after
the prevalence survey from May 2009 to April 2011.
Incident cases (those negative on the prevalence survey
and positive in the Clinical Survey but who developed
ACE after the three-stage prevalence survey) were trea-
ted as true negatives since they were negative during
the prevalence survey. SIII was conducted twice on
those that were positive in SII of the prevalence survey
(i.e. within the prevalence survey and the validation/
Clinical Survey – because SIII was the Clinical Survey/
”gold standard”) and subjects were classified positive
for ACE if they were positive in either of the two SIII
assessments.Analysis
Estimation of Sensitivity
Sensitivities were estimated as: TP/(TP+FN), where TP =
True Positive (i.e., positive on prevalence survey and
Clinical Survey) and FN = False Negative (i.e., negative
on prevalence survey but positive on Clinical Survey).
The sensitivities of SI (single stage) and (SI & SII) (two-
stage) and the (SI & SII & SIII) (three-stage) methods
were evaluated against the Clinical Survey. For example,
the sensitivity of the three-stage method was the propor-
tion of individuals who were positive in all stages (SI+,
SII+, SIII+) in the prevalence survey among those identi-
fied as cases of ACE in the Clinical Survey.Estimation of Specificity
Specificity was estimated as: TN/(TN+FP), where TN =
True Negative (i.e., those negative in both the prevalence
and Clinical Surveys) and FP = False positive (positive in
the prevalence survey but negative in the Clinical Sur-
vey). The specificities of single, two and three-stage
methods were estimated. For the three-stage method the
specificity is 100% since there are no false positives (be-
cause SIII of the prevalence survey is the Clinical Sur-
vey). For the single and two-stage methods, specificity
may be less than 100%. In addition we estimated the
proportions of false positives (1-specificity) and false
negatives (1-sensitivity).Expenditure comparison study
We compared the financial expenditure of a two-stage
survey (in which a clinical diagnosis is made by experi-
enced clinicians on those identified as SI positive by lay
field personnel) and the current three-stage epilepsy sur-
vey. Our analyses were based on the SI and SII positive
proportions and the marginal expenditure incurred in
the three-stage survey of 2008. In both situations, we
assumed that the first stage (SI) would not incur any ex-
penditure since it is embedded within on-going census.
For the two-stage survey, SII would be the definitive
stage since it is conducted by clinicians using the clinical
history tool used in SIII of the three-stage survey.
All analyses were performed in STATA version 11
(StataCorp, College Station, TX, USA).Ethical considerations
The study protocol was explained to all participants by
the interviewing clinicians. Written informed consent
was obtained from all participants or their caregivers if
they were less than 18 years of age. The study was
approved by the Kenya Medical Research Institute/ Na-
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Figure 1 Flow of subjects in the Clinical Survey.
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Flow of validation subjects in the Clinical Survey
The Clinical Survey targeted a sample of 5488 partici-
pants who completed both SI and SII of the prevalence
survey. Of these, 1046 (19.1%) were lost to follow-up:
629 (60.1%) had moved, 225 (21.5%) could not be traced,+ 
121
+                        –
23   98                    
+ – + –






Figure 2 Response status of subjects within the prevalence and Clinic119 (11.4%) refused consent and 70 (6.7%) had died,
while 3 (0.3%) were found to have been duplicate
records (Figure 1). The reasons for loss to follow-up
were ascertained from the regularly updated HDSS
population and vital events register.
Of 4442 subjects screened in the Clinical Survey, 18
ACE cases identified during the Clinical Survey were
negative in the prevalence survey i.e. the 4321 (SI-) and
98 (SI+, SII-) (Figure 2). The reasons for the 18 false
negatives were: i) 15 were negative in SI (reported no
history of convulsions) but the Clinical Survey docu-
mented that they had convulsions which occurred be-
fore the prevalence survey and therefore should have
been identified as potential cases; ii) the remaining 3
subjects were positive in SI but were classified as febrile
convulsions in SII. We interviewed 13 of the 15 false
negatives (negative in SI) with a stigma scale [31]. All
the 13 respondents had high perceived stigma (based on
a 66th percentile cut-off in the same epilepsy popula-
tion) compared to the other cases of ACE of whom only
33% felt stigmatized [31].
Sensitivity and Specificity
Sensitivity decreased and specificity increased with the
number of stages. The three-stage method (SI & SII
&SIII) had sensitivity of 48.6 % but with a specificity of
100.0 % (Table 1). Sensitivity was highest for the one-
stage (SI) screening method (57.1 %), but it also had the
lowest specificity (97.7 %). Sensitivity and specificity esti-
mates of combinations of various stages within the
three-stage methodology are displayed in Table 1.
Expenditure comparison study
From the proportion of respondents who were positive
in SI (2.2%), we estimated that we would require to
follow-up 6183 people in SII of the study. In the three-4,321     –








Table 1 Estimation of the sensitivity and specificity of the single- and multi-stage survey methodologies using the
Clinical Survey as gold standard
Method Sensitivity, 95% CI Specificity, 95% CI TP FN FP TN
One-stage (SI) 57.1 39.4 – 73.7 97.7 97.2 – 98.1 20 15 101 4306
Two-stage (SI & SII) 51.4 32.4 – 67.6 99.9 99.7 – 100.0 18 17 6 4401
Three-stage (SI & SII & SIII) 48.6 31.4 – 66.0 100.0 – † 17 18 † 0 4407
TP=true positive; FP=false positive; FN=false negative; TN=true negative.
†TP and FP are derived from 2nd SIII/Clinical Survey on those that were SII+ (i.e. SIII was done twice on the SII+ participants).
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personnel), this would take 29.4 months to complete at
a cost of USD 109,120 (Table 2). In the two-stage
method (in which SII is conducted by clinicians), screen-
ing the 6183 people positive in SI would take 42.1
months and cost USD 171,922, which is 1.6 times more
expensive than the three-stage method (Table 3).Table 2 Estimates of the expenditure of the three-stage surve
Stage II field work




No of SI cases 5152.4 515.2
20% Follow-up* 1030.5 103
Sub-total 1 6182.9 618.3
Stage II transport costs
Duration
Follow-up FW days




SII +ve rate (%) 21.8
No of SII cases 1125.1
Duration†
No screened Clinic days
No of SII +ve cases 1125.1 160.7
No screened in SII 1125.1 160.7
Total Expenditure
*Assume that at least 20% of the SI positive cases will be followed up in the field a
† Both SII and SIII run concurrently therefore the total duration is 29.4 months.
1) One field worker interviews 10 participants per day on average.
2) One working month = 21 working days.
3) A fieldworker's salary is Ksh 25,000 per month.
4) The study clinician interviews/assesses 7 participants per day.
5) A clinician's salary is Ksh 75,000 per month.
6) 1 USD = 80 Ksh.
7) FW = Field work.
8) Transport costs:
a) Distance/day: estimated at 200km.
b) Cost per = Ksh 60/km (vehicle).Discussion
The three stage method had a low sensitivity of 48.6%,
but cost 63% of the two stage survey. Sensitivities were
slightly higher for the one-stage (57.1%) and two-stage
(51.4%) methods. Specificities were marginally lower in
single-stage (97.7%) compared to the three-stage method
(100%). It would be important to improve the sensitivityy conducted by lay field personnel
Expenditure















Table 3 Estimates of the expenditure of the two-stage survey conducted by clinicians
Stage II field work
SI +ve rate (%) 2.2
SI Population 233,881
Duration Expenditure
Follow-up FW days FW months Salary (Ksh) Salary (USD)
No of SI cases 5152.4 736.1 35.1 2,628,775 32,860
20% Follow-up* 1030.5 147.2 7 525,755 6572
Sub-total 1 6182.9 883.3 42.1 3,154,530 39,432
Stage II transport costs
Duration Costs
Follow-up FW days FW months Cost (Ksh) Cost (USD)
No cases followed up 6182.9 883.3 42.1 10,599,220 132,490
Sub-total 2 883.3 42.1 10,599,220 132,490
Total Expenditure 13,753,749 171,922
*Assume that at least 20% of the SI positive cases will be followed up in the field at least twice.
1) One field worker interviews 10 participants per day on average.
2) One working month = 21 working days.
3) A fieldworker's salary is Ksh 25,000 per month.
4) The study clinician interviews/assesses 7 participants per day.
5) A clinician's salary is Ksh 75,000 per month.
6) 1 USD = 80 Ksh.
7) FW = Field work.
8) Transport costs:
a) Distance/day: estimated at 200km.
b) Cost per = Ksh 60/km (vehicle).
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mates of prevalence obtained using the current three
stage method can be adjusted to allow for the low sensi-
tivity where this method is likely to be useful due to lo-
gistical and cost considerations e.g. in HDSS sites.
In this study, we examined a population-based three-
stage system for detecting ACE (where a subject was
classified as a case if they were positive in all the three
stages). Other studies have validated only hospital-based
survey methods [17,20,32] or determined the validity of
a screening tool (within a three-stage method) in detect-
ing epileptic seizures but not epilepsy [12]. Unlike the
validation of population-based studies, generalization of
validation parameters of hospital-based studies is limited
by selection bias (due to overrepresentation of cases with
more severe forms of epilepsy). Additionally, people who
lack knowledge of epilepsy may fail to seek treatment
and therefore are not captured in hospital-based valida-
tions. Other limitations in hospital-based validation
studies are inadequate sample sizes and they may not
represent the field situation. Thus these studies therefore
provide less accurate (often inflated) estimates of sensi-
tivity than population-based validation [12]. The valid-
ation of population-based methods is applied directly
to a wider population, hence the findings are more
generalizable, although this is usually costly. Furthermore,
compared to validation of population-based studies, thevalidity of hospital-based studies may not be influenced
by stigma-related concealment of seizures.
The precision of the validation depends upon the sam-
ple size, which for our study was statistically determined
and was larger than for other validation studies
[17,32,33]. In our study, the number of false positives
was highest in SI; since the SI questions targeted all (in-
cluding febrile) convulsions. Even a small proportion of
false positives in a large population would have consider-
able logistical and cost implications. For instance, 2.3%
of false positives among this study population of 233,880
individuals results to 5379 false positive individuals that
would otherwise have to be screened in SIII of the
prevalence survey. Inclusion of SII substantially reduces
the false positives screened in SIII, which in our study
declined from 2.3% to 0.1%.
We found that multi-stage methods (SI&SII and
SI&SII&SIII) had poorer sensitivity than SI alone. This
was observed in another validation study where (like in
our study) if only epilepsy specific questions were used,
sensitivity was substantially lower (and the specificity
higher) than when questions on epilepsy and other sei-
zures were used [33,34]. These observations suggest that
questions about seizures under any circumstances are
important in avoiding false negatives.
In our study, stigma-related non-response could be
the main cause of the low sensitivity of the three-stage
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ceived stigma scores for all the false negatives com-
pared to the epilepsy population (those identified in the
prevalence survey) in which only 33% felt stigmatized
[31]. Stage I (which contributed the largest proportion
of false negatives i.e. 15/18) was conducted by HDSS
field staff who are usually resident in the study commu-
nity and who were also involved in the routine re-
enumerations within the study area. The sensitivity of
SI may also depend on the cultural setting (e.g. SI
screening questions might be more frequently misinter-
preted in communities with low literacy levels) and the
skills of the field staff in administering sensitive ques-
tions (pertaining to a stigmatized condition). For ex-
ample, the percentage of false negatives was much
lower (23.4%) in an Australian when a screening ques-
tionnaire was administered to study known (physician
diagnosed) epilepsy cases [35]. In contrast, the clinical
survey (our “gold standard”) was conducted by clini-
cians experienced in the diagnosis of epilepsy, of whom
individuals with epilepsy or their guardians may have
been more trusting and/or have expected benefits such
as treatment or advise. A high sensitivity (79.3%) was
estimated in another field validation in which rural doc-
tors conducted an equivalent of SII of our prevalence
survey [12]. However, it is difficult to compare our val-
idation with this study due to differences in case defini-
tions and sources of cases [12,17].
A lack of awareness of convulsions in family mem-
bers by the household heads could also have led to
the low sensitivity of SI. Household heads (or their
spouses) were the primary respondents in the HDSS
re-enumeration. Individuals identified as having con-
vulsions by the household head in SI (or their care-
takers if they were children or cognitively impaired)
were interviewed in the subsequent survey stages and
in the Clinical Survey.
Three cases of epilepsy were lost in the prevalence sur-
vey between SI and SII because field personnel who con-
ducted SII were unable to distinguish between febrile
and non-febrile convulsions. The sensitivity of the three-
stage method could therefore be improved by better
training the SII field staff to distinguish between differ-
ent types of convulsions.
A two-stage epilepsy survey conducted by clinicians
would be more expensive and of longer duration than a
three-stage survey in which the initial stages are carried
out by non-medical field personnel. This is because
medically trained personnel require higher salaries and
lack the field-work experience of lay field workers.
However, for this additional expenditure, the improve-
ment in sensitivity would be limited. Only false nega-
tives in SII would be eliminated and so the sensitivity
would at best be equivalent to the sensitivity of SI.Limitations of the study
A major limitation of this study was the attrition of sub-
jects over the two years of the Clinical Survey. These
losses were observed despite efforts to locate individuals.
There were, however, no differences in age, sex and SI
status (either positive or negative in SI of the three-stage
screening) between those lost and those that completed
the study.
There could have been an increase in awareness of
epilepsy in this population following the three-stage
prevalence survey. This could have reduced stigma and
increased knowledge of epilepsy, yielding more positive
responses within the Clinical Survey, since the latter sur-
vey was conducted over a 2 year period after the preva-
lence survey. This hypothesis is supported by a study
conducted on the same population after the prevalence
survey which reported only moderate levels of perceived
stigma [31].
Conclusion
There is an urgent need to obtain accurate assessment
of the burden of neuropsychiatric conditions in regions
of the world where it is difficult to obtain statistics. We
have shown that a three-stage method can be used to
screen large populations for these conditions during a
census in an efficient and cost-effective manner, pro-
vided the sensitivity of first stage questions is high or the
loss of sensitivity at this stage can be adjusted. Stigma-
related concealment of potential cases could be
decreased with community sensitization and education.
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